Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Deals channel feed
Biogen's $7.3B deal for Reata followed a bidding war with mysterious 'Party A'
Last year
Pharma
Incyte axes blood cancer collab with Syros
Last year
R&D
Senti Bio offloads manufacturing site to Hong Kong PE firm for $38M
Last year
Manufacturing
Novo Nordisk snaps up Inversago Pharma for up to $1B+ on the back of megablockbuster Wegovy sales
Last year
Regeneron to buy gene therapy biotech Decibel Therapeutics in small $109M deal
Last year
Cell/Gene Tx
SPAC eureKING acquires another manufacturer
Last year
Manufacturing
Merck enlists Astex to search for p53 cancer drug in expanded deal
Last year
Ginkgo Bioworks nets second contract with Merck
Last year
Manufacturing
Ikena inks small cash grab in all-stock deal for Pionyr to take cancer drug on Hippo pathway
Last year
Startups
BARDA orders more smallpox and mpox vaccines from Bavarian Nordic
Last year
Pharma
Manufacturing
Details emerge on Cidara/J&J influenza partnership, with a countdown on next steps
Last year
Pharma
Updated: Seagen deprioritizes antibody-drug candidate from $4.2B Merck deal
Last year
Agios to take over Alnylam’s preclinical siRNA blood disorder asset in a deal worth $147.5M
Last year
R&D
Novartis, Ionis will work together again in the next-generation cardio space
Last year
Bausch + Lomb CEO Brent Saunders searches for smaller deals while 'digesting' $1.75B Xiidra move
Last year
Martin Shkreli's old companies secure $650,000 deal to sell Daraprim amid bankruptcy
Last year
Pharma
ProQR finds eye disease partner in Europe, hands off two late-stage candidates
Last year
Pharma
BARDA awards Emergent 10-year, $704M contract for Ebola treatment
Last year
Manufacturing
TG Therapeutics signs $645M deal to kick-start international launch of MS antibody
Last year
Updated: EQRx sells itself to another Alexis Borisy company, Revolution Medicines, in all-stock deal
Last year
A deal? An asset sale? A launch? Everyone is watching next moves for Roivant, BridgeBio
Last year
Pharma
Biogen makes its move, announcing a $7.3B deal for Reata
Last year
AstraZeneca picks up Pfizer’s rare disease gene therapies, taps new R&D leader as Mene Pangalos steps down
Last year
People
Ipsen ends neurotoxin pact with Galderma after arbitration cases filed in international court
Last year
Law
First page
Previous page
30
31
32
33
34
35
36
Next page
Last page